Headline: Bio-Techne Corp. Q2 Profit Surges 15% to $120M, Shares Rise

[Para 1: The Lead] Bio-Techne Corp. (NASDAQ: BIO) reported a 15% increase in Q2 profits to $120 million, surpassing analyst estimates, on 4th February 2026. The company's strong performance in its life sciences and diagnostics segments contributed to the earnings boost, signaling robust growth in the biotechnology sector. [Para 2-3: Supporting details & Context] Revenue for the quarter climbed 20% to $300 million, driven by a 25% increase in sales of its life sciences products and a 10% growth in diagnostics. Bio-Techne's stock price rose 7% in after-hours trading following the release of the earnings report. The company's CEO highlighted the resilience of its customer base and the ongoing demand for its solutions, attributing the success to strategic investments in research and development. Bio-Techne's strong financials and market leadership position it for continued growth in the competitive biotechnology industry.